iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Eris Lifesciences Q3 PAT grows 11.7% YoY to Rs 100 cr

28 Jan 2022 , 02:37 PM

Consolidated profit before tax stood at Rs 108.9 crore in Q3 FY22, rising 9.75% from Rs 99.2 posted in the same quarter last year. EBITDA grew by 13.5% year on year to Rs 121.7 crore in Q3 FY22. Meanwhile, the drug companys EBITDA margin improved to 36.6% in Q3 FY22 from 34.5% in Q3 FY21.

The company said it grew at 7.8% in Q3 FY22 as compared to IPM growth of 5.7%, outperforming IPM in cardio-metabolic, CNS & womens health therapies.

Shares of Eris Lifesciences were trading 0.36% lower at Rs 706.30 on BSE. The result was announced during market hours today, 28 January 2022.

Eris Lifesciences is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian pharmaceutical market.

Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.